Assessment of prevalence of different histopathological patterns of injury in patients with immune check-point inhibitor-associated colitis and their association with specific immune check-point inhibitors
Latest Information Update: 15 Dec 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- 15 Dec 2021 New trial record